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Steven Trifilio,1,2 Irene Helenowski,1 Meghan Giel,3 Barbara Gobel,4 Judy Pi,2
Deborah Greenberg,2 Jayesh Mehta1The use of a neutropenic diet (ND) after hematopoietic stem cell transplantation (HSCT) was instituted
more than 30 years ago as a means of preventing infection from organisms colonizing the gastrointestinal
tract. Evidence supporting this practice is lacking, however, and the actual efficacy of the ND remains
unknown. Institutional policy at Northwestern Memorial Hospital discontinued the use of ND in 2006.
We conducted a retrospective study of 726 consecutive HSCT recipients, 363 who received an ND and
363 who received a general hospital diet, to determine the incidence of microbiologically confirmed infec-
tions during and after transplantation. Our findings indicate a higher rate of infections in the HSCTrecipients
who received an ND.
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Infectious complications during hematopoietic
stemcell transplantation (HSCT) are a sourceof serious
morbidity andmortality. Disruption of the gastrointes-
tinal (GI)mucosa from intensive chemotherapy, immu-
nosuppression, and prolonged neutropenia place
HSCT recipients at risk for GI infections. For more
than 30 years, neutropenic diets (NDs) have been used
as a protective measure to prevent potential pathogens
fromcontaminating foodbyproviding a sourceof infec-
tion after HSCT. The American Society for Blood and
MarrowTransplantation evidence-based guidelines for
the prevention of infectious complications recommend
an ND after HSCT, with caveats that this recommen-
dation is based on observations within the general pop-
ulation, thepotential for food-bornepathogens to cause
infection has not been supported by published clinical
trials in the HSCT recipient population, and the
potential benefit of the ND must be weighed against
the patient’s quality of life and nutritional needs [1].
Most transplantation centers still include anND in
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6/j.bbmt.2012.02.015ern Memorial Hospital empirically replaced its ND
with an Academy of Nutrition and Dietetics-approved
general hospital diet (GD). The GD retains restric-
tions for uncooked meat, fish, and some unpasteurized
dairy products but allows fresh fruits, vegetables, and
other foodstuffs.We retrospectively analyzed 726 con-
secutive HSCT recipients, including 363 patients who
received an ND and 363 patients who received a GD.
The primary objective of this study was to evaluate the
effects of the GD and the ND on the incidence of mi-
crobiologically confirmed infections.METHODS
Data on microbial infections were obtained from
the electronic medical records of 726 consecutive hos-
pitalized HSCT recipients, 363 who received an ND
and 363 who received a GD during neutropenia.
Data on antibiotic administration were obtained
from pharmacy records. Patient data were recorded
from the day of hospital admission up to the day of
hospital discharge. Upon hospital admission, all pa-
tients received ciprofloxacin, a triazole antifungal,
and acyclovir for prophylaxis. Patients who developed
febrile neutropenia were started on empiric cefepime
or piperacillin/tazobactam therapy at the discretion
of the managing team. Antibiotic management was
modified based on each patient’s clinical situation
and microbial culture results. Recipients of matched
sibling allografts routinely received cyclosporine be-
ginning on day –1 before transplantation, whereas re-
cipients of matched unrelated allografts received1385
Table 1. Demographic Data
t Characteristics ND GD P Value
Number of patients 363 363
Age, years, median (range) 57 (18-78) 57 (18-76) .99
Males:females, n 216:147 210:153 .71
Diagnosis, n (%)
Myeloma 191 (53) 197 (54) .71
Non-Hodgkin lymphoma 67 (18) 69 (19) .92
AML 63 (17) 59 (16) .77
Hodgkin’s disease 18 (5) 15 (4) .72
Acute lymphoblastic leukemia 5 (1.4) 6 (1.6) .55
Other 19 (5) 19 (5) .99
Conditioning regimen, n (%)
Melphalan (200 mg/m2) 191 (53) 197 (54) .71
BEAM (BCNU/etoposid/
cytarabine/melphalan)
52 (14) 47 (13) .67
Busulfan/cyclophosphamide 25 (7) 8 (2) .0037
Busulfan/fludarabine 38 (10) 49 (13) .25
Melphalan (100/m2) ± cytoxan 33 (9) 39 (11) .53
Carboplatinum/etoposide 12 (3) 16 (4) .56
Etoposide (30 mg/kg) 4 (1.1) 1 (0.3) .06
Type of HSCT, n (%)
Autologous 276 (76) 267 (74) .49
Allogeneic 87 (24) 96 (26) .49
Matched sibling donor 52 38
Matched unrelated donor 35 58 .01
Myeloablative 50 (14) 57 (16) .53
Reduced intensity 37 (10) 39 (11) .90
Days to engraftment, median 12 (3) 12 (3) .99
Neutropenic fever, n (%) 213 (72) 219 (60) .70
Start of antibiotic therapy, days
post-HSCT, median
8 (2.2) 8 (2.2) .99
Duration of antibiotic therapy,
days, median
5 (1.4) 5 (1.4) .99
Cefepime, n (%) 263 (72) 231 (64) .02
Piperacillin/tazobactam, n (%) 57 (16) 71 (20) .20
Vancomycin, n (%) 195 (54) 204 (56) .55
Corticosteroids, n (%) 53 (15) 62 (17) .42
1386 Biol Blood Marrow Transplant 18:1385-1390, 2012S. Trifilio et al.tacrolimus. In addition, patients who underwent full
myeloablative conditioning received methotrexate 15
mg/m2 on day 11, followed by 10 mg/m2 on days
13, 16, and 111, whereas those with nonmyeloabla-
tive conditioning received mycophenolate mofetil
1gam orally twice daily. All positive microbial cultures
identified from the onset of neutropenia until hospital
discharge were included in the analysis, except for sin-
gle coagulase-negative Staphylococcus epidermidis
(CONS) isolates, which were considered contami-
nants. All patients with diarrhea were tested for toxi-
genic Clostridium difficile by toxin A and B assays and
stool culture. Gastrointestinal graft-versus-host dis-
ease (GVHD) was diagnosed by tissue biopsy analysis
in most cases (.80%) and by endoscopy and clinical
evaluation in the remainder. Routine rectal and nasal
surveillance cultures were collected weekly. Neutro-
penic fever was defined as any temperature .101F
or 2 temperatures .100.5 F within a 1-hour period
and an absolute neutrophil count\500 cells/mL. Cor-
ticosteroid use was defined as any corticosteroid (.10
mg methylprednisolone equivalent) given beyond the
normal corticosteroid dose used to prevent nausea
and vomiting during the conditioning regimen. The
ND excluded all fresh fruits and vegetables as well asblack pepper, raw and undercookedmeats and cheeses,
cold smoked fish, raw or unpasteurized dairy products,
raw miso products, raw grain products, and brewer’s
yeast. The microbial GD is a general diet that man-
dates safe food handling practices and permits black
pepper and well-washed fresh fruits and vegetables
but excludes raw tomatoes, seeds, and grains. The
other restrictions remain. In addition to these restric-
tions, the registered dietitian provided food safety ed-
ucation to all HSCT recipients during hospitalization.
The ND was used between October 2004 and August
2006 and the GD, between September 2006 and Au-
gust 2008. The ND was initiated around the time of
neutropenia. The patients reverted to a GD diet
once neutropenia resolved, except those with GI
GVHD. Descriptive statistics were used for all study
variables. Inferential statistical analysis was performed
using the Fisher exact test and the c2 test for nominal
data and the Student t test for interval data. Odds ratios
and 95% confidence intervals were calculated based on
multivariate logistic regression analysis. The study was
approved by NorthwesternMemorial Hospital’s Insti-
tutional Review Board.RESULTS
Demographic data for the 726 HSCT recipients
(363 ND treated and 363 GD treated patients) are
shown in Table 1. There were no significant differ-
ences in baseline demographic data between the ND
and GD groups in terms of age, sex, diagnosis, type
of transplant (autologous or allogeneic), number of
empiric antibiotics initiated for neutropenic fever, me-
dian days of antibiotic treatment, incidence rate of
neutropenic fever, time to neutropenic fever, time to
engraftment, or length of hospital stay. A significantly
greater number of GD-treated patients underwent
matched unrelated donor HSCT compared to
matched sibling donor within the ND treated group
(P\ .0078). A greater number of ND treated pateints
were conditioned with busulfan and cytoxan, whereas
a greater number of GD treated patients were condi-
tioned with busulfan and fludarabine; overall busulfan
use was similar between the 2 groups. Cefepime was
used more often in the ND group, whereas piperacil-
lin/tazobactam was used more often in the GD group.
Overall broad-spectrum b-lactam use was similar in
the 2 groups.
As shown in Table 2, overall there were signifi-
cantly fewer microbiologically confirmed infections
in the GD group (P \ .0272), which was especially
evident after the resolution of neutropenia (P\ .008).
Diarrhea was more common in the ND group (P\
.095), as were urinary tract infections (P \ .003).
Overall hospital length of stay was similar in the 2
groups; however, the ND group spent more days in
Table 2. Results
ND GD P Value
Total microbiologically confirmed
infections, n
135 106 .03
During neutropenia, n 100 85 .22
After resolution of neutroepenia, n 35 16 .01
Diarrhea, n 294 276 .10
Grade II-IV acute GI GVHD, n 19 10 .13
Hospital length of stay, days (range) 18 18
Autologous (overall LOS) 16 (10-73) 16 (8-71)
Autologous (day of engraftment
to day of discharge)
5 4
Allogeneic (over LOS) 26 (12-92) 26 (14-160)
Allogeneic (day of engraftment
to day of discharge)
10 9
Overall mortality, n 17 18 .58
Biol Blood Marrow Transplant 18:1385-1390, 2012 1387Neutropenic Diet after HSCTthe hospital after engraftment, both auto-HSCT recip-
ients (5 days versus 4 days) and allo-HSCT recipients
(10 days versus 9 days). Overall mortality was similar
in the 2 groups.
Table 3 lists the microbial isolates detected both
during and after the resolution of neutropenia before
hospital discharge. During neutropenia, no between-
group differences in microbiologically confirmed in-
fections were seen, although a trend toward a greater
number of Gram-negative organisms was observed in
the ND group (P\ .089). The ND group had a sig-
nificantly higher rate of infection after the resolution
of neutropenia. C. difficile and vancomycin-resistant
Enterococcus faecium (VRE) were more frequent in the
ND group (P \ .060 and P \ .068, respectively).
A subset analysis of auto-HSCT recipients found no
significant difference in total microbiologically con-
firmed infections (P \ .109) between the ND and
GD groups. The ND group had a significantly higher
rate of infections that could be attributed to a GI
source (ie, VRE, C. difficile, and Enterobacteriaciae)Table 3. Microbiologically Confirmed Isolates
Infectious Agent
Neutropenic Period,
ND GD
Coagulase-negative Staphylococcus 7 (1.9) 7 (1.9)
Streptococcus viridans 16 (4) 11 (3)
VRE 10 (3) 12 (3)
Enterococcus faecalis 6 (1.6) 3 (0.8)
Methicillin-resistant Staphylococcus aureus 2 (0.6) 5 (1.4)
Methicillin-sensitive Staphylococcus aureus 1 (0.3) 2 (0.6)
Corynebacterium 2 (0.6) 3 (0.8)
Bacillus spp 0 1 (0.3)
Gemella 0 2 (0.6)
Escherichia coli 10 (2.7) 6 (1.6)
Pseudomonas aeroginosa 0 3 (0.8)
Stenotrophomonas maltophilia 2 (0.6) 0
Enterobacter 2 (0.6) 0
Other Gram-negative organisms 4 (1.1) 1 (0.3)
Clostridium difficile 35 (9.6) 29 (8)
Candida spp 3 (0.8) 1 (0.3)
Rhizopus nigricans 0 1 (0.3)
Saccaromyces 0 1 (0.3)
Histoplasma capsulatum 0 1 (0.3)
Herpes simplex virus 0 1 (0.3)
Mycobacterium (ns) 0 0(P \ .042), as well as a trend toward a higher rate
of VRE infections (P\ .054).
Table 4 displays the results of weekly surveillance
cultures. There was no between-group difference in
the number of patients colonized with various bacteria
from any anatomic area, but the GD group had signif-
icantly more surveillance mold cultures. Overall, the
percentage of patients with positive surveillance cul-
tures who subsequently had an identical positive cul-
ture at a distant anatomic site was not significantly
different between the 2 groups.
Acute grade II-IVGIGVHDwasmore frequent in
the ND group at 60 days posttransplantation (47%
versus 20%; P\ .11). Within the ND group, previous
C. difficile infection was observed in 9 of the 19 patients
with GVHD. Nonrelapse mortality was 78% in that
ND subgroup.
DISCUSSION
Infections occurring during the immediate period
before and after HSCT cause significant morbidity
and mortality. Compromised integrity of the GI
mucosa due to chemotherapy and radiation has con-
ventionally been considered a source of bacterial inva-
sion and infection after HSCT [1]. Uncooked fruits
and vegetables have been identified as potential sources
of infection with drug-resistant opportunistic patho-
gens after chemotherapy [2,3]. Intuitively, low-
microbial or ‘‘neutropenic’’ diets with varying degrees
of dietary restrictions were implemented to decrease
the bacterial load available for infection. The hypothe-
sis that eliminating host gut flora during allo-HSCT
could mitigate the effects of GVHD was first tested
in animal studies at the University of Notre Dame’s
Lobund Laboratory in the 1960s. Germ-free micen (%) Nonneutropenic Period, n (%)
P Value ND GD P Value
.99 3 (1) 1 (0.3) .62
.62 2 (0.7) 1 (0.3) .99
.83 7 (2) 1 (0.3) .07
.51 1 (0.3) 0 .99
.41 1 (0.3) 4 (1.1) .06
.99 1 (0.3) 1 (0.3) .99
.37 1 (0.3) 0 .99
.99 0 1 (0.3) .99
.5 0 0 .99
.45 0 0 .99
.25 5 (1.4) 2 (0.6) .45
.5 1 (0.3) 0 .99
.5 0 0 .99
.06 2 (0.6) 2 (0.6) .99
.51 9 (2.5) 2 (0.6) .06
.62 1 (0.3) 0 .99
.99 0 0 .99
.99 0 0 .99
.99 0 0 .99
.99 1 (0.3) 0 .99
.99 0 1 (0.3) .99
Table 4. Surveillance Cultures and Infection
Surveillance Culture ND GD P Value
VRE (rectal), n (%) 82 (23) 71 (20) .35
MSSA (nasal), n (%) 15 (4) 17 (4) .85
MRSA (nasal), n (%) 6 (1.6) 11 (3) .50
Gram-negative organisms (ESBL rectal), n (%) 7 (1.9) 9 (2.5) .77
Mold (nasal), n (%) 2 (0.6) 11 (3) .02
VRE infection with previous positive
surveillance culture, n
8 6 .99
MSSA infection with previous positive
surveillance culture, n
2 1 .59
MRSA infection with previous positive
surveillance culture, n
1 2 .59
Mold infection with previous positive
surveillance culture, n
0 0 .99
ESBL indicates extended-spectrum b-lactamase; MRSA, methicillin-
resistant Staphylococcus aureus; MSSA, methicillin-sensitive S. aureus.
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secondary disease compared with conventional alloge-
neic chimeras, suggesting that GVHD reactions were
not necessarily fatal if the host flora could be restricted
or eliminated [4]. Data from UCLA and elsewhere re-
ported in the 1970s identified fresh fruits and vegeta-
bles as sources of bacterial and fungal contamination,
which led to gut decontamination studies [5]. Over
the past 3 decades, several classes of antibiotics have
been used routinely for prophylaxis during HSCT,
with varying degrees of success. The effects of this
practice on the development of multidrug-resistant in-
fections and changes to gutmicrobiota need to be reex-
amined. A 2000 survey of community cancer centers
found that 78% (n 5 120) of the institutions placed
their neutropenic patients on a restricted diet [6].
More recently, a 2011 survey of stem cell transplanta-
tion centers revealed that all responding institutions
(n 5 15) continued to use NDs (Steven Trifilio,
NMH, 12/28/201, personal communication).
To our knowledge, the present study is the first and
only study conducted in HSCT recipients to evaluate
the effectiveness of an ND in preventing hospital in-
fections. Our overall results show that maintaining
an ND did not reduce infection, but was actually asso-
ciated with an increased risk for infection, especially
after resolution of neutropenia. Overall survival did
not differ between the 2 treatment groups.
Our results are comparable to, and expand the re-
sults of, a randomized trial conducted in 153 patients
admitted for treatment of newly diagnosed AML who
were randomly assigned to receive a cooked diet or
a diet containing fresh fruits and vegetables (raw diet)
[7]. The rates of serious infection and death were sim-
ilar in the 2 study arms, and the authors concluded that
no benefit was derived from the cooked diet [7].
Findings from another recent study of 20 patients
with leukemia maintained on a restricted diet
also showed no significant increase in the rates of
infection or gut colonization by Gram-negative bacte-
ria [8]. Finally, a small study of neutropenic patients(n 5 28) conducted in an outpatient setting found no
differences in febrile episodes and positive blood cul-
tures between the patients who were compliant with
an ND and those who were not [9].
It should be noted that the severity of GI toxicity
caused by transplantation conditioning regimens is
significantly greater than that associated with standard
AML induction regimens. The aforementioned leuke-
mia study [8] reported a 10%-20% rate of grade 3-4
mucositis and diarrhea after induction chemotherapy,
whereas studies of HSCT conditioning regimens typ-
ically report .50% grade 3-4 toxicity, .85% ulcer
formation, and almost universal diarrhea [10]. If the
ingestion of contaminated food puts neutropenic pa-
tients at risk for infection via entry through a severely
damaged mucosa, then GI toxicity after HSCT condi-
tioning regimens should provide the optimal condi-
tions for observing this effect. Our present findings
do not support this long-held belief.
Published reports from in vitro, animal, and human
studies have elaborated data on the interactions be-
tween enteric microorganism pathogenicity and sup-
pression of normal gut microflora and have given rise
to the concept of ‘‘colonization resistance’’ [11]. Multi-
ple pathways for inhibiting pathogenicity contribute to
the maintenance of normal gut symbiosis. Deficient
gut microflora volume and inflammation caused by an-
tibiotics and chemotherapy agents disrupt the regula-
tion of normal enteric microbial communication and
allow for the emergence of intrinsic enteric pathogen
infections [12]. It can be speculated that the ND diet
has a higher microbial content, and thus that in the set-
ting of broad-spectrum antimicrobial prophylaxis and
therapy, this diet could contribute to decreased resis-
tance to colonization by virulent microorganisms and
ultimately increase the risk for infection.
As noted earlier, the infection rate was higher in the
ND group compared with the GD group after the res-
olution of neutropenia. Changes to the intestinal mi-
crobiota induced by a change in diet would not be
expected to occur immediately after initiation of an
ND. Similarly, these ND-induced changes would not
resolve, with a return to normal gut flora, immediately
after resolution of neutropenia. Experimental data in
mice indicate complete displacement of the normal in-
testinal microbiota, allowing for the growth of patho-
genic organisms after antibiotics and exogenously
administered VRE [13]. The study also reported simi-
lar dramatic changes to the gut flora in 2 allo-HSCT
recipients colonized with VRE. The effects began sev-
eral days after the start of treatment and persisted for
several weeks; infection occurred several days after
changes in gut colonization were noted [13].
Data have been reported supporting altered gut
colonization and infection in pediatric cancer patients
on restricted diets [14]. Indirect evidence linking a re-
stricted diet to infections associated with changes to
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Figure 1. C. difficile infection and diet.
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types of infection detected in the present study.
Antibiotic use was similar in our ND and GD
groups, but urinary tract infections were more fre-
quent in the ND group. Urinary tract infections are
most commonly caused by pathogenic bacteria origi-
nating from the GI tract. Changes to normal gut
microbiota could allow for the emergence of patho-
genic bacteria within the GI tract and subsequent
urinary tract infection.
C. difficile–associated disease (CDAD) also was
more frequent in theND group (Figure 1). The associ-
ation between CDAD and alterations in the intestinal
microbiota from antibiotic use, diet, and cancer and
other comorbid diseases is well established. The main-
tenance of normal gut flora through the use of probiot-
ics has been shown to reduce CDAD recurrence rates
[15-18]. VRE bacteremia also was more frequent in
the ND group. VRE colonization and infection have
been directly attributed to changes in the normal
intestinal microbiota [19,20]. Taken together, our
findings suggest that decreased bacterial volume
might contribute to the risk of infection associated
with changes to the intestinal microbiota. Prospective
studies are needed to evaluate whether an ND alone
alters gut colonization after HSCT.
The rate of acute grade II-IV GI GVHD was
higher in the ND group, although the difference be-
tween the groups did not reach statistical significance.
An association between GVHD and ND has not been
reported previously. Almost one-half of the patients in
the ND group who subsequently developed GVHD
had a previous C. difficile infection, and nonrelapse
mortality was very high in this group. Nutritional sup-
port guidelines for patients with GI GVHD, which are
also on common sense, include a low-microbial diet
[14]. Prospective trials are needed to determine
whether this practice is warranted.Currently, there are no published quality-of-life
studies which have compared a neutropenic diet with
a general diet during stem cell transplantation. Within
our institution, the change to a GD was well received
by patients and nutrition support service and food
and nutrition service personnel. In a limited number
of cases, patients who were treated during the transi-
tion period when ND was being replaced by GD and
who experienced both diets emphatically stated they
preferred the GD, because it was less restrictive in
terms of food choices and was easier to maintain their
caloric needs (data not shown). Nutrition support and
food services benefited financially from the perspective
of the ability to purchase, prepare, and manage a single
hospital-wide diet.
The results of the present study are limited by the
nonrandomized (although well-matched) patient pop-
ulation and are applicable only to the ND used at
Northwestern Memorial Hospital, which may differ
from those of other institutions. The heterogeneity
of transplant types and ABO and extended RBC phe-
notypes precluded any meaningful statistical analysis
of these variables. Other factors that might predispose
this subset of continually hospitalized patients to late
infection remain to be identified.
Our findings suggest no benefit in maintaining
a low-microbial diet. If our findings are confirmed,
a major change in an established, but non–evidence-
based, practice will be needed. An added benefit of
the more liberal diet would be greater palatability,
which might contribute to a reduced use of parenteral
nutrition and consequent improved quality of life.ACKNOWLEDGMENT
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